ICP
VRTX icon

Interchange Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Interchange Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2
Closed -$10K – 1080
2020
Q4 		$10K Buy
+2
New +$459 0.01% 801

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Interchange Capital Partners's VRTX Position: Q1 2026 in Review

Interchange Capital Partners increased its Vertex Pharmaceuticals (VRTX) stake by 48% in Q1 2026, buying an estimated $139K and bringing the position to 919 shares worth $443K. The position accounts for 0.14% of the portfolio, ranked #156.

Interchange Capital Partners first reported a position in VRTX in Q4 2020 and has held it in 11 quarters since. The position peaked at $698K in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Interchange Capital Partners held 919 shares of Vertex Pharmaceuticals worth $443K as of Q1 2026.
  • Interchange Capital Partners bought 299 Vertex Pharmaceuticals shares in Q1 2026, an estimated $139K.
  • Vertex Pharmaceuticals made up 0.14% of Interchange Capital Partners's portfolio in Q1 2026, its #156 holding.
  • Interchange Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
  • Interchange Capital Partners's Vertex Pharmaceuticals position peaked at $698K in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Interchange Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.